Speaker Profile

D.O., Neuro-Oncologist, Henry Ford Health System

Biography
Dr. Snyder is a Neuro-Oncologist at the Hermelin Brain Tumor Center of Henry Ford Health System dedicated to improving access to innovative clinical trials and comprehensive multidisciplinary care. Dr. Snyder specializes in the care of people with cancer or tumors involving the nervous system. He is a leader in the brain, spine, and molecular tumor boards for the health system. Dr. Snyder is active in all phases of clinical trials as well as translational research, including: epigenomics, radiomics, and clinical data curation to drive real-world-evidence and precision medicine initiatives. Dr. Snyder has been recognized for his work addressing access to care barriers for the neuro-oncology community through virtual connectivity and a disease navigation virtual tumor board platform. First and foremost, Dr. Snyder is a committed advocate for his patients, their families, and the neuro-oncology community, driving patient-centric innovation and progress.


 Session Abstract – PMWC 2020 Silicon Valley


The Molecular Tumor Board (MTB) was mostly established to facilitate the incorporation of molecular diagnostics into the consideration of appropriate therapies for patients with late stage cancer. Initially, much of the deliberation was focused on understanding the results of such testing, as reporting of results was limited in scope and frequently understandable only to cutting edge experts in the field. Improved, but still not perfect, reporting now exists, so discussion has shifted to prognostic and therapeutic considerations. That said, the collective experience with rare mutations and off label therapies is still such that collective wisdom is necessary. This brings up the issue of how MTBs collect, share, and preserve data within a specific MTB, and perhaps more importantly, how it might be shared amongst MTBs and beyond. While initial activity related to MTBs resided almost exclusively in large academic, and select community, medical centers, there is now significant effort in the commercial setting as well, with a number of intriguing efforts presently underway. Important and evolving issues, such as defining which patients are most likely to benefit from the efforts of a MTB, Virtual MTBs, and the generation of Real World Evidence, will be discussed.